My ePortfolio Register   

Resistance of ER-positive breast cancer to tamoxifen therapy may be driven by APOBEC3B

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.12.15
Views: 878
Rating:

Dr Reuben Harris - Howard Hughes Medical Institute, Minneapolis, USA

Dr Harris presents, at a press conference at SABCS 2015 discussing the latest data on APOBEC3B. 

The data shows responses to tamoxifen were significantly prolonged by reducing levels of the enzyme APOBEC3B in preclinical models of oestrogen receptor–positive breast cancer, additionally there were significantly shortened by increasing levels of APOBEC3B, suggesting that APOBEC3B drives resistance to tamoxifen.

Read the news article here 

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence